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Abstract 
The personal gut microbiota is characterized by species composition, by enterotype and by 
gut bacterial gene counts. Gut microbiota can be viewed as a complex micro-ecosystem. 
Regulation of the diversity and stability of the gut microbiota therefore is critical for the 
development of future therapies. The areas with high potential for personalised management 
of gut microbiota are obesity and the metabolic syndrome, prevention and control of 
(recurrent) infections, immune mediated disorders, and the gut-brain axis. A true and deeper 
understanding of the interaction between the microbiota and the host, as well as a better 
matching of probiotic and prebiotic mechanisms with clinical indication will be required for 
successful future implementation of these therapies. 
 
 
 
 
Introduction 
During the co-evolution of man and microbes, the human intestinal tract is colonised by some 
thousand species of bacteria.  Gut borne microbes outnumber the total of body tissue cells by 
a factor of ten. Recent metagenomics analysis of the human gut microbiota has revealed the 
presence of some 3.3 million genes, as compared to the mere 23 thousand genes present in the 
cells of the human body tissues [1]. On average, each individual has approximately 540 000 
of the initial 3.3 million genes.  Similarity between individuals is reflected in the core 
metagenome genes : ~50 % of an individual’s genes are shared by at least 50 % of individuals 
of the cohort.  On the other hand, individuality is determined by rare genes : the genes shared 
by less than 20 % of individuals encompass 2.4 million genes. Thus, we (our gut microbiota) 
are all rather similar but not identical. Based on the sequenced metagenomes, individuals can 
be grouped into three robust clusters (referred to as enterotypes). Each enterotype is 
characterized by a different bacterial ecosystem; with high abundance of either Bacteroides, 
Prevotella or Ruminococcus [2,3] .  
People may differ by species composition, by enterotype but also by gut bacterial gene 
counts. Humans intestinal microbiota thus share large similarities but also differences that 
permit stratification, with potential applications in personalized or digitized medicine and 
nutrition. 
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Me, myself, I by Joan Armatrading was a signature song of the 1980s. By now, we realize that 
man lives in intimate association with its gut microbiota, and not alone. The cover story of 
The Economist (18th August 2012) on gut microbiota therefore appropriately was entitled Me, 
myself, us. 
 
Perturbation of the intestinal microbiota may lead to chronic diseases such as auto-immune 
diseases, colon cancers, gastric ulcers, cardiovascular disease and obesity. Restoration of the 
gut microbiota may be difficult to accomplish, but the use of pro- and prebiotics has led to 
promising results in a large number of well-designed (clinical) studies (reviewed elsewhere in 
this volume). Microbiomics has spurred a dramatic increase in scientific, industrial and public 
interest in probiotics and prebiotics as possible agents for gut microbiota management and 
control. Genomics and bioinformatics tools may allow us to establish mechanistic 
relationships between gut microbiota and the health status of the individual, hopefully 
providing perspectives for personalised gut microbiota management. 
  
The above themes were addressed in an international workshop (www.gutmicrobiota.org 13-
15 September 2012,  Maastricht, The Netherlands)  by taking various different angles, ranging 
from transitions in ecosystems to microbe-microbe and microbe-host interactions. Basic 
scientists (microbiology, immunology, systems biology) were teamed with clinical and 
nutritional specialists to pave the road to personalised gut microbiota management.  
 
Gut microbiota can be viewed as a complex micro-ecosystem. The work of the group of 
Marten Scheffer has shown that the stability of complex macro-ecosystems such as rainforests 
or lakes is maintained by common regulatory mechanisms which can be mathematically 
approached [4]. The mathematical model predicting loss of stability has been used by 
Salvador Dali in his last painting, The Swallow’s Tail in 1983 (Figure 1). By using these 
models it also can be predicted under which circumstances the system will lose its resilience, 
even when it reaches the tipping point [5,6]. The gut microbiota may be an ecosystem to 
which these same rules apply. It thus could be approximated how introduction of new 
(probiotic) species could lead to restoration of the stability and equilibrium of gut microbiota, 
but also when it could lead to its destruction. Regulation of the diversity and stability of the 
gut microbiota therefore is critical for the development of future therapies. The challenges for 
four areas of future therapy derived from the microbiome which were discussed during the 
workshop are summarized below.  
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Obesity and metabolic syndrome 
Obesity is threatening the world; it’s becoming one of the most serious health problems of the 
21st century with increasing prevalence in both adults and children and is one of the leading 
causes of death. Obesity is associated with metabolic syndrome, which can lead to type 2 
diabetes. Both authorities and scientists are looking for ways to prevent people from 
becoming obese, but also to prevent the incidence of health problems related to obesity, such 
as type 2 diabetes which is irreversible. Host and environmental factors that affect the energy 
balance are major determinants. During the past five to ten years it has become clear that the 
human microbiota may play a role as well. 
 
It started with the work of the group of Jeffrey Gordon at Washington University, who 
showed an association between obesity and changes in the relative abundance of two 
dominant bacterial divisions in the microbiota: Firmicutes and Bacteroidetes [7]. In obese 
mice, the ratio between Firmicutes and Bacteroidetes was in favour of the Firmicutes, whereas 
the microbiota of the lean mice harboured relatively more Bacteroidetes. The same 
association was found in the microbiota of obese and lean human individuals. More strikingly, 
transplantation of an ‘obese microbiota’ into germfree mice, led to a significantly higher 
increase in body fat then the colonization with a ‘lean microbiota’[8]. Other studies showed a 
shift in the microbiota when obese individuals lost weight; the relative abundance of 
Firmicutes decreased, whereas the amount of Bacteroidetes increased and the ratio became 
more similar to that of lean individuals. Although these studies show a strong association 
between obesity and the microbiota composition, European studies have until today not 
confirmed these results [9].  
The transplantation of faeces was recently also executed in the FATLOSE trial at the 
Amsterdam Medical Center AMC, where obese men were transplanted with lean donor 
faeces. The results showed a significant increase in peripheral insulin sensitivity after the 
transplantation [10]. Faecal transplant may not be the ideal solution in the end , but it is a first 
step towards microbiota management that leads to improvement in clinical symptoms. 
Besides microbiota composition, the diversity or richness seems also to be relevant in health 
and health-related problems. Evidence is accumulating that a more diverse microbiota is 
related to health, whereas in disease, the diversity often seems to be decreased. [1]  
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Rather than overall diversity, presence or absence of specific species is associated with health 
and disease. Akkermansia muciniphila, Faecalibacterium prausnitzii, and Bacteroides 
vulgatus are among the species being extensively studied for potential associations with 
health and disease. When strong associations can be determined between the abundance of 
such species and health-related problems, these microbes can become biomarkers. 
As indicated above, individuals differ in gut microbiota species composition, enterotype and 
gene count. Recent research has shown that obese patients with a low gene count will be less 
susceptible to a low caloric diet than those with a high gene count. Furthermore, a higher 
inflammatory tone was found in association with a low gene count as well as elevated markers 
of risk of co-morbidities [11,12].  
Diversity or gene count and the presence or absence of specific microbial species can become 
biomarkers and thus tools in the diagnosis and prognosis of obese patients. Besides, these 
markers can be relevant in personalized strategies for nutrition and medicine, for microbiota 
modulation and perhaps in the prediction of disease risk in healthy persons. Probiotics, 
prebiotics and also synbiotics alone will never be sufficient to restore the disequilibrium 
between energy intake and energy expenditure [13]. However, as microbiota management 
tools they can become a part of the total fight against obesity and related health problems in 
the near future. 
 
(Recurrent) infections  
Worldwide hundreds of millions of individuals are suffering from infections, often recurrent 
in nature, caused by bacteria, viruses and parasites.  Examples are Clostridium difficile 
infections (CDI), urinary tract infections, bacterial vaginosis, upper respiratory tract 
infections, malaria and HIV.  
With microbiomics  it is possible to collect relatively cheaply and rapidly enormous amounts 
of genetic and biological data of microbiota, including benign and pathogenic microorganisms 
and their host. With these data it will progressively be possible to develop rapid and cheap 
diagnostic techniques that will allow for more dedicated therapeutic interventions [14]. In turn 
these dedicated, perhaps personalised, therapies will also be largely derived from 
microbiomics and will be directed towards re-establishing a healthy microbial community 
[15]. 
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The microbial community in the gut is a dynamic entity that ideally, by its so-called 
colonisation resistance protects us from infection. A good example is the predisposition of 
patients to develop CDI upon treatment with antibiotics that can disrupt and destabilise the 
normal bowel microbiota. CDI is increasing, apparently due to frequent use of antibiotics and 
the resulting extensive damage to the indigenous microbiota. Transplantation of faeces from a 
healthy donor, so called faecal bacteriotherapy, has been used successfully in severe cases of 
recurrent CDI, but there are risks of transmitting pathogens with this therapy [16].  
Microbiomics could be employed successfully to sort out, perhaps even on the level of 
individual patients, which combination of gut dwelling bacteria should be selected for a 
dedicated and safe probiotic therapy to cure recurrent CDI. Similar approaches could be 
followed to cure some of the other recurrent infections, such as vaginosis and urinary tract 
infections. 
 
A good example is presented in a recent paper by Abreu et al. [17], in which it was shown by 
comparative microbiome profiling that chronic rhinosinusitis (CRS) was caused by 
Corynebacterium tuberculostearicum, a common skin inhabitant. A probiotic strain of 
Lactobacillus sakei, isolated from the sinus resident microbiota, when applied as a nose spray, 
proved to be effective in preventing sinusitis in mice. In this case, microbiomics was used to 
generate genetic and biological information leading to identification of a very specific 
bacterial strain as a candidate for therapeutic intervention. 
 
In summary, microbiomics are the driving force behind novel diagnostic and 
bacteriotherapeutic  methods  that in future will allow to combat an array of infectious 
diseases on the level of the individual patient. 
 
Immune related disorders  
Immune related disorders encompass a broad category of diseases ranging from those which 
are characterized by an overactive Th2 system (allergies) to Th1 dominated autoimmune 
diseases. The hallmark of inflammatory bowel diseases such as ulcerative colitis and Crohn’s 
disease is the ongoing mucosal inflammation. Jean Francois Bach 10 years ago in his now 
classic paper showed how immune related disorders have increased over half a century [18]. 
This trend has continued over the past decade [19].  
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In virtually all immune mediated disease an abnormal composition of gut microbiota has been 
found. However, whether this is cause or consequence is hard to establish. In a number of 
cases, such as allergy, the abnormal development of gut microbiota precedes clinical onset of 
disease. The outcome of probiotic intervention in a number of immune mediated diseases is 
discussed elsewhere in this book. In a number of instances, clinical success has been obtained 
in prevention, and even management of immune mediated diseases. However, also variable 
results have been obtained, even in nearly identical designed studies [20,21]. These different 
outcomes have been attributed to genetic differences in the host, differences in the 
environment, or in composition of gut microbiota. Observations by Sarah Lebeer indicated 
that even differences can exist between different formulations of the same probiotic strain, in 
this case Lactobacillus rhamnosus GG; differential centrifugation may lead to loss of surface 
pili, the structures which are essential for adhesion to mucous surfaces [22]. 
An alternative way for microbiota management is use of prebiotics. Prebiotics currently are 
being developed which mimic the size, linkage, and partly the building blocks and prebiotic 
functions of human milk oligosaccharides. Prebiotics by now also have been demonstrated to 
have direct or indirect immunomodulatory effects. Direct interaction of prebiotics with cells 
of the mucosal immune system can take place via lectins and lectin like receptors. Galectins 
are a category of soluble type lectins that may bind galactose/ β-glycoside containing glycans. 
Intestinal epithelial cells express galectins 2,3,4,6,7 and 9 abundantly in vivo. Emerging 
evidence indicates that galectins (intracellular or secreted) are regulators of immune 
homeostasis and inflammation: they facilitate cell-cell/matrix adhesion, induce T-cell 
apoptosis and promote chemotaxis. Administration of  Bifidobacterium breve (TLR9 
inducing) in combination with  non-digestible oligosaccharides (galectin 9 inducing) reduces 
risk factors for asthma and respiratory allergy in infants [23].  
The parallel development of the gut microbiome and the mucosal immune system during the 
first weeks and months of life [24,25] offers a window of opportunity for intervention early in 
life.  Primary prevention of allergic diseases by neonatal administration of probiotics and/or 
prebiotics indeed has shown to be effective in a number of studies. The challenge for the 
future will be to target probiotics for existing immune mediated disorders. For that, more 
insight into mechanisms and molecules, disease heterogeneity, other microbiotas (skin [26], 
lung [27], oral, genital [28]), and risk/benefits will be needed. 
 
8 
Gut-Brain Axis 
Functional gastrointestinal disorders (FBD) are defined by symptom-based diagnostic criteria 
attributed to the gastrointestinal tract in the absence of pathologically-based disorders [29].  
Many published data showing perturbed microbiota composition in FBD and in particularly in 
irritable bowel syndrome (IBS). The general conclusion is that changes in the microbiota may 
contribute to symptoms in FBD [30].  However, the exact etiology and pathophysiology of 
IBS is still unknown but many hypotheses/mechanisms which play role have been put 
forward: dysregulation of the brain-gut-axis and autonomic nervous system, visceral 
hypersensitivity, alterations in gut microbiota, altered levels of gastrointestinal neuropeptides 
and hormones, abnormal gastrointestinal motility, environmental and psychological factors 
(stress), and low-grade intestinal inflammation possibly related to alterations in gut 
microbiota [31]. 
A bidirectional neurohumoral communication system, known as the gut-brain-axis, integrates 
the host gut and brain activities [32]. The intestinal microbiota communicates with the brain 
via this axis to influence brain development and behavior. This might influence a broad 
spectrum of diseases, including IBS, psychiatric disorders and demyelating conditions such as 
multiple sclerosis [33]. Putative mechanisms by which bacteria access the brain and influence 
behavior include bacterial products that gain access to the brain, via cytokine release from the 
mucosal immune cells, via the release of gut hormones such as 5-HT from endocrine cells, or 
via afferent neural pathways, including the vagus nerve. Stress and emotions can also 
influence the microbial composition of the gut through the release of stress hormones or 
sympathetic neurotransmitters that influence gut physiology and alter the habitat of the 
microbiota. Alternatively, host stress hormones such as noradrenalin might influence bacterial 
gene expression or signaling between bacteria, and this might change the microbial 
composition and activity of the microbiota [33]. 
 In the near future research will be focused on the causal relationship between gut 
microbiota composition and the behavioral phenotype in animal and human studies. 
Personalised phenotypic characterization of the aberrations along the gut-brain axis will need 
to be investigated. Probiotics and prebiotics can be used in treatment of IBS, however,  many 
questions remain (what strains, who can qualify, how long should treatment last, etc..). 
Crucial will be understanding of  mechanisms of microbiota modulation, and modulation of 
barrier function is one of these. The effects of bacterial and host metabolites (tryptophan 
metabolites, fermentation products such as propionic acid, serine proteases) on the function of 
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the gut should be elucidated, which also includes production of neurotransmitters by bacteria 
(GABA, noradrenaline, dopamine, acetylcholine and 5-HT). Fecal transplant methods might 
be interesting to investigate the pre- and post-transplant behavioral changes in animal and 
even in human studies. 
 Because stress plays an essential role in IBS, future research should also be focused on 
stress mechanisms: direct effects of microbiota on the HPA-axis. ‘Dysbiosis’ which could 
have both direct ENS as well as CNS effects and vice versa. Attention should also be directed 
towards mast cells which play an important role in neural pathways and immunity as well as 
in gut barrier function. 
  It can be concluded that more translation to human (clinical) research will be needed.  
More focus should be put on the small bowel with respect to microbiota composition and 
small bowel mucosa interactions. Furthermore, whether live or dead microbes should be used 
for this purpose remains to be determined. As in other cases of gut microbiota management, 
there is a need for relevant biomarkers and surrogate markers. Especially for intervention in 
the gut brain axis, risk determinants and safety issues, e.g. in children, are of importance. 
 
Summary and Conclusions 
 
The interest for probiotics, and gut microbiota in general, by the scientific community has 
virtually exploded during the last decade. This is evidenced by the establishment of large 
research consortia, an overwhelming amount of publications in the highest-ranking journals, 
and data leading to new insights and possibilities for treatment of hitherto poorly understood 
diseases. The interest of the public at large for this subject can be derived from Google Ngram 
viewer. This tool allows for an analysis of the word count of all of Google Books. The data 
presented in Figure 2 clearly show the exponential growth in the use of the word probiotics 
over the last 2 decades. On the other hand, the scaling of the Y-axis learns us to be humble: 
current use of probiotics is 1: 5 million printed words (for comparison: love is used 1: 5,000, 
hate 1:50,000).    
Major challenges lie ahead, such as a true and deeper understanding of the microbiota, and a 
better matching of probiotic mechanisms with clinical indication, to name just a few. Pivotal 
for any use of probiotics is the health benefit. A major target for probiotics therefore are the 
healthy at increased risk, being it because of life style, age, genetic or environmental 
influences (Figure 3). During every stage of research leading to new possibilities of 
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(personalized) gut microbiota management, society should be informed of risks and benefits 
and unreasonable expectations should be managed. The road to personalized gut microbiota 
management will be long and winding, but the destiny makes it worthwhile.  
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Figures 
 
 
Figure 1. Regulatory mechanisms for complex ecosystems, including lakes (upper right), 
rainforests (lower right) and gut microbiota (lower left). Upper left panel depicts Dali’s 
interpretation of the mechanisms governing catastrophes. Upper right photograph courtesy of 
Mag. A. Frauwallner, Graz, Austria, lower left Dr. J. Doré, INRA, Micalis Institute, Jouy-en-
Josas,  France, lower right R. Lievendag, Middelburg, The Netherlands. 
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Figure 2. The use of the terms microbiota and probiotics in literature as assessed by Google 
Ngram viewer. Period covered is 1940-2008.  
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Figure 3. Variables contributing to personalised gut microbiota management. 
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